Clinical Trials Logo

Clinical Trial Summary

Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells and may enhance activity of topotecan in patients with previously treated small cell lung cancer and improve progression free survival.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00698516
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 2
Start date July 2008
Completion date May 2010

See also
  Status Clinical Trial Phase
Completed NCT00046111 - A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors Phase 1
Enrolling by invitation NCT06293833 - Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan N/A
Completed NCT00259935 - A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors Phase 1
Completed NCT01037023 - Regulatory Hycamtin(Oral) PMS N/A
Active, not recruiting NCT04986670 - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer N/A
Completed NCT00997061 - SCOT Registry: Small Cell Lung Cancer Treatment and Outcome N/A
Completed NCT00276276 - Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer Phase 3
Not yet recruiting NCT05320458 - Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer N/A
Active, not recruiting NCT05228496 - A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC Phase 2
Completed NCT00316186 - First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin Phase 2
Not yet recruiting NCT04440800 - Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Treatment
Terminated NCT03499678 - Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
Terminated NCT01313663 - A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population Phase 2
Active, not recruiting NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Phase 1
Completed NCT00043862 - The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC) Phase 2
Completed NCT00320359 - Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer Phase 3
Recruiting NCT06228326 - A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs Phase 1
Completed NCT04314895 - Trial of NanoPac Intratumoral Injection in Lung Cancer Phase 2